Free Trial

BioLineRx (BLRX) Stock Price, News & Analysis

BioLineRx logo
$0.27 +0.02 (+7.12%)
As of 05:45 PM Eastern

About BioLineRx Stock (NASDAQ:BLRX)

Key Stats

Today's Range
$0.26
$0.31
50-Day Range
$0.20
$0.55
52-Week Range
$0.19
$1.58
Volume
76.91 million shs
Average Volume
55.69 million shs
Market Capitalization
$21.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

BLRX MarketRank™: 

BioLineRx scored higher than 64% of companies evaluated by MarketBeat, and ranked 461st out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioLineRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioLineRx's stock forecast and price target.
  • Earnings Growth

    Earnings for BioLineRx are expected to grow in the coming year, from ($0.15) to ($0.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioLineRx is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioLineRx is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioLineRx has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.04% of the outstanding shares of BioLineRx have been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently decreased by 10.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioLineRx does not currently pay a dividend.

  • Dividend Growth

    BioLineRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.04% of the outstanding shares of BioLineRx have been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently decreased by 10.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioLineRx has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for BioLineRx this week, compared to 1 article on an average week.
  • Search Interest

    Only 8 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioLineRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.10% of the stock of BioLineRx is held by insiders.

  • Percentage Held by Institutions

    Only 1.56% of the stock of BioLineRx is held by institutions.

  • Read more about BioLineRx's insider trading history.
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com
BLRX: Ayrmid Assumes Commercialization Efforts
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
BioLineRx Reports Strategic Moves in Q3 2024
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BiolineRx Ltd. Announces New Direct Offering of Shares
See More Headlines

BLRX Stock Analysis - Frequently Asked Questions

BioLineRx's stock was trading at $0.2140 at the start of the year. Since then, BLRX stock has increased by 27.9% and is now trading at $0.2738.
View the best growth stocks for 2025 here
.

BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Tuesday, May, 28th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.28. The biotechnology company earned $6.86 million during the quarter, compared to analyst estimates of $0.34 million. BioLineRx had a negative net margin of 90.57% and a negative trailing twelve-month return on equity of 163.37%.

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

Last Earnings
5/28/2024
Today
1/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLRX
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+3,132.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-60,610,000.00
Pretax Margin
-90.57%

Debt

Sales & Book Value

Annual Sales
$21.99 million
Book Value
$0.18 per share

Miscellaneous

Free Float
79,060,000
Market Cap
$22.26 million
Optionable
Optionable
Beta
1.39
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:BLRX) was last updated on 1/3/2025 by MarketBeat.com Staff
From Our Partners